Cart
sales@molnova.com
NIBR-17
CAS No. 944396-88-7
NIBR-17( —— )
Catalog No. M27568 CAS No. 944396-88-7
NIBR-17 is a pan class I PI3K inhibitor. NIBR-17 inhibits PI3KKα, PI3KKβ, PI3KKγ, and PI3KKδ with IC50 of 1 nM, 9.2 nM, 9 nM, and 20 nM respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 263 | In Stock |
|
| 5MG | 223 | In Stock |
|
| 10MG | 332 | In Stock |
|
| 25MG | 532 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNIBR-17
-
NoteResearch use only, not for human use.
-
Brief DescriptionNIBR-17 is a pan class I PI3K inhibitor. NIBR-17 inhibits PI3KKα, PI3KKβ, PI3KKγ, and PI3KKδ with IC50 of 1 nM, 9.2 nM, 9 nM, and 20 nM respectively.
-
DescriptionNIBR-17 is a pan class I PI3K inhibitor. NIBR-17 inhibits PI3KKα, PI3KKβ, PI3KKγ, and PI3KKδ with IC50 of 1 nM, 9.2 nM, 9 nM, and 20 nM respectively.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorDEPTOR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number944396-88-7
-
Formula Weight380.4
-
Molecular FormulaC18H20N8O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOc(cc1)ncc1Nc1cc(-c2cnc(N)nc2)nc(N2CCOCC2)n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Hou Y, et al. Design, Synthesis, and Biological Evaluation of Icaritin Derivatives as Novel Putative DEPTOR Inhibitors for Multiple Myeloma Treatment. J Med Chem. 2021 Oct 28;64(20):14942-14954.
molnova catalog
related products
-
GDC-0077
GDC-0077 (RG-6114) is a potent, highly isoform selective inhibitor of PI3Kα, with IC50 of 0.038 nM.
-
LY294002
A classic, broad-spectrum PI3K inhibitor with IC50 of 0.5/0.57/0.97 uM for PI3Kα/δ/β, respectively.
-
iMDK
iMDK quarterhydrate is a potent PI3K inhibitor that inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate synergistically inhibits non-small cell lung cancer (NSCLC) with MEK inhibitors without harming normal cells and mice.
